- Home
- CWK vs RYTM Comparison
CWK vs RYTM Comparison
Compare CWK & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- RYTM
- Stock Information
- Founded
- CWK 1784
- RYTM 2008
- Country
- CWK United Kingdom
- RYTM United States
- Employees
- CWK N/A
- RYTM N/A
- Industry
- CWK Real Estate
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CWK Finance
- RYTM Health Care
- Exchange
- CWK Nasdaq
- RYTM Nasdaq
- Market Cap
- CWK 3.0B
- RYTM 3.5B
- IPO Year
- CWK 2018
- RYTM 2017
- Fundamental
- Price
- CWK $11.65
- RYTM $56.07
- Analyst Decision
- CWK Hold
- RYTM Strong Buy
- Analyst Count
- CWK 5
- RYTM 10
- Target Price
- CWK $15.50
- RYTM $66.90
- AVG Volume (30 Days)
- CWK 1.6M
- RYTM 388.8K
- Earning Date
- CWK 02-20-2025
- RYTM 02-26-2025
- Dividend Yield
- CWK N/A
- RYTM N/A
- EPS Growth
- CWK N/A
- RYTM N/A
- EPS
- CWK 0.56
- RYTM N/A
- Revenue
- CWK $9,446,500,000.00
- RYTM $112,530,000.00
- Revenue This Year
- CWK $1.06
- RYTM $66.58
- Revenue Next Year
- CWK $6.43
- RYTM $44.63
- P/E Ratio
- CWK $20.79
- RYTM N/A
- Revenue Growth
- CWK N/A
- RYTM 81.55
- 52 Week Low
- CWK $9.24
- RYTM $35.17
- 52 Week High
- CWK $16.11
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- CWK 31.06
- RYTM 42.18
- Support Level
- CWK $12.60
- RYTM $56.03
- Resistance Level
- CWK $13.47
- RYTM $58.65
- Average True Range (ATR)
- CWK 0.41
- RYTM 1.87
- MACD
- CWK -0.14
- RYTM -0.27
- Stochastic Oscillator
- CWK 2.96
- RYTM 5.45
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.